VIRACTA THERAPEUTICS

viracta-therapeutics-logo

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
#SimilarOrganizations #People #Financial #Event #Website #More

VIRACTA THERAPEUTICS

Social Links:

linkedin

Linkedin

twitter

Twitter

Industry:
Biopharma Biotechnology Medical Pharmaceutical Therapeutics

Founded:
2007-01-01

Address:
Cardiff By The Sea, California, United States

Country:
United States

Website Url:
http://www.viracta.com

Total Employee:
11+

Status:
Active

Contact:
(858)400-8470

Email Addresses:
[email protected]

Total Funding:
194.9 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Apache Wordpress Plugins


Similar Organizations

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.


Current Advisors List

roger-pomerantz_image

Roger Pomerantz Chair Of The Board Of Directors @ Viracta Therapeutics
Board_member
2020-06-01

patrick-soon-shiong_image

Patrick Soon-Shiong Board Of Director @ Viracta Therapeutics
Board_member

frederick-dotzler_image

Frederick Dotzler Board @ Viracta Therapeutics
Board_member

steve-rubino_image

STEVE RUBINO Independent Member, Board of Directors @ Viracta Therapeutics
Board_member
2021-03-01

michael-huang_image

Michael Huang Board of Directors @ Viracta Therapeutics
Board_member

Current Employees Featured

ronald-berenson_image

Ronald Berenson
Ronald Berenson Co-founder & CEO @ Viracta Therapeutics
Co-founder & CEO

not_available_image

Lisa Rojkjaer
Lisa Rojkjaer Chief Medical Officer & MD @ Viracta Therapeutics
Chief Medical Officer & MD
2020-05-01

not_available_image

George Stamatoyannopoulos
George Stamatoyannopoulos Co-Founder and Director @ Viracta Therapeutics
Co-Founder and Director

ivor-royston_image

Ivor Royston
Ivor Royston CEO & President @ Viracta Therapeutics
CEO & President
2015-01-01

douglas-v-faller_image

Douglas V Faller
Douglas V Faller Scientific Founder; Chair, Scientific Advisory Board @ Viracta Therapeutics
Scientific Founder; Chair, Scientific Advisory Board
2018-01-01

not_available_image

George Hillman
George Hillman COO, VP & Co-Founder @ Viracta Therapeutics
COO, VP & Co-Founder

dan-chevallard_image

Dan Chevallard
Dan Chevallard Chief Operating Officer and Chief Financial Officer @ Viracta Therapeutics
Chief Operating Officer and Chief Financial Officer

Founder


douglas-v-faller_image

Douglas V Faller

not_available_image

George Hillman

not_available_image

George Stamatoyannopoulos

ivor-royston_image

Ivor Royston

ronald-berenson_image

Ronald Berenson

Stock Details


Company's stock symbol is NASDAQ:VIRX

Acquisitions List

Date Company Article Price
2020-11-30 Sunesis Pharmaceuticals Sunesis Pharmaceuticals acquired by Viracta Therapeutics N/A

Investors List

oxford-finance-corporation_image

Oxford Finance LLC

Oxford Finance LLC investment in Post-IPO Debt - Viracta Therapeutics

silicon-valley-bank_image

Silicon Valley Bank

Silicon Valley Bank investment in Post-IPO Debt - Viracta Therapeutics

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Post-IPO Equity - Viracta Therapeutics

logos-capital_image

Logos Capital

Logos Capital investment in Post-IPO Equity - Viracta Therapeutics

surveyor-capital_image

Surveyor Capital

Surveyor Capital investment in Post-IPO Equity - Viracta Therapeutics

lifesci-venture-partners_image

LifeSci Venture Partners

LifeSci Venture Partners investment in Post-IPO Equity - Viracta Therapeutics

amoon_image

aMoon Fund

aMoon Fund investment in Post-IPO Equity - Viracta Therapeutics

sectoral-asset-management_image

Sectoral Asset Management

Sectoral Asset Management investment in Post-IPO Equity - Viracta Therapeutics

ridgeback-capital_image

Ridgeback Capital

Ridgeback Capital investment in Post-IPO Equity - Viracta Therapeutics

bvf-partners_image

BVF Partners

BVF Partners investment in Post-IPO Equity - Viracta Therapeutics

Key Employee Changes

Date New article
2020-03-25 Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Official Site Inspections

http://www.viracta.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.08 K

  • Host name: 104.21.54.133
  • IP address: 104.21.54.133
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Viracta Therapeutics" on Search Engine

dfkcompany.com © 2022. All rights reserved